Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill temporarily limits how drug rebates work under the 340B Program.
The problem
The 340B Program allows certain healthcare providers to buy discounted drugs. Concerns exist about how rebates are used and whether current rules need temporary changes.
The proposal
The bill would temporarily restrict or modify how rebates function under the 340B drug discount program administered by the Public Health Service.
The impact
Drug manufacturers, hospitals, clinics, and patients may be affected through changes in drug pricing, program costs, and healthcare provider operations.
Limiting rebate misuse could lower medication prices for patients and healthcare systems. This might increase drug affordability for vulnerable populations relying on 340B providers.
Temporary limits could create oversight of how rebates are managed. This may ensure 340B discounts actually benefit patients and safety-net providers as intended.
Restrictions might prevent abuse of the discount system. Safeguards could ensure the 340B Program continues serving uninsured and low-income patients effectively.
Hospitals and clinics use rebates to fund patient care services. Limiting rebates could reduce money available for safety-net healthcare providers serving poor communities.
Restricting 340B rebates might cause manufacturers to raise prices on other drugs. Patients without 340B access could face higher medication costs overall.
A temporary limit leaves programs unsure about long-term operations and funding. Healthcare providers may struggle to plan budgets without knowing final rules.
The bill has no official summary provided. Without specifics, impacts cannot be fully assessed or understood by stakeholders.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.